UBS AM
ARVN icon

UBS AM’s Arvinas ARVN Stock Holding History

UBS AM’s Portfolio ARVN Stock Details ARVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$914K Sell
109,966
-1,008
-0.9% -$9.4K ﹤0.01% 2371
2026
Q1 		$1.18M Sell
110,974
-13,347
-11% -$165K ﹤0.01% 2281
2025
Q4 		$1.47M Sell
124,321
-791
-0.6% -$8.64K ﹤0.01% 2000
2025
Q3 		$1.07M Sell
125,112
-57,499
-31% -$436K ﹤0.01% 1982
2025
Q2 		$1.34M Sell
182,611
-720,314
-80% -$5.31M ﹤0.01% 2309
2025
Q1 		$6.34M Buy
902,925
+469,394
+108% +$7.36M ﹤0.01% 1446
2024
Q4 		$8.31M Buy
433,531
+3,047
+0.7% +$74K ﹤0.01% 1337
2024
Q3 		$10.6M Sell
430,484
-692
-0.2% -$18.1K ﹤0.01% 1192
2024
Q2 		$11.5M Buy
431,176
+236,680
+122% +$7.54M ﹤0.01% 1077
2024
Q1 		$8.03M Sell
194,496
-38,121
-16% -$1.67M ﹤0.01% 1078
2023
Q4 		$9.57M Buy
232,617
+71,911
+45% +$1.68M ﹤0.01% 999
2023
Q3 		$3.16M Sell
160,706
-868
-0.5% -$21.3K ﹤0.01% 1407
2023
Q2 		$4.41M Hold
161,574
– – ﹤0.01% 1290
2023
Q1 		$4.41M Sell
161,574
-6,115
-4% -$193K ﹤0.01% 1290
2022
Q4 		$5.74M Buy
167,689
+9,072
+6% +$382K ﹤0.01% 1123
2022
Q3 		$7.06M Buy
158,617
+107,473
+210% +$5.22M ﹤0.01% 1084
2022
Q2 		$2.15M Buy
51,144
+5,327
+12% +$267K ﹤0.01% 1587
2022
Q1 		$3.08M Buy
45,817
+2,445
+6% +$167K ﹤0.01% 1571
2021
Q4 		$3.56M Buy
43,372
+962
+2% +$78.3K ﹤0.01% 1566
2021
Q3 		$3.49M Sell
42,410
-1,600
-4% -$141K ﹤0.01% 1539
2021
Q2 		$3.39M Buy
44,010
+11,197
+34% +$777K ﹤0.01% 1587
2021
Q1 		$2.17M Buy
32,813
+8,825
+37% +$675K ﹤0.01% 1715
2020
Q4 		$2.04M Sell
23,988
-164,219
-87% -$5.66M ﹤0.01% 1676
2020
Q3 		$4.44M Sell
188,207
-271,576
-59% -$7.87M ﹤0.01% 1200
2020
Q2 		$15.4M Buy
459,783
+152,413
+50% +$6.47M 0.01% 806
2020
Q1 		$12.4M Buy
307,370
+301,370
+5,023% +$14.1M 0.01% 807
2019
Q4 		$247K Buy
+6,000
New +$176K ﹤0.01% 2420

Other funds holding ARVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM's ARVN Position: Q2 2026 in Review

UBS AM reduced its Arvinas (ARVN) stake by 0.91% in Q2 2026, selling an estimated $9.4K and leaving 109,966 shares worth $914K. The position accounts for ﹤0.01% of the portfolio, ranked #2371.

UBS AM first reported a position in ARVN in Q4 2019 and has held it in 27 quarters since. The position peaked at $15.4M in Q2 2020. 201 funds tracked by Wall St. Rank hold ARVN as of Q2 2026.

  • UBS AM held 109,966 shares of Arvinas worth $914K as of Q2 2026.
  • UBS AM sold 1,008 Arvinas shares in Q2 2026, an estimated $9.4K.
  • Arvinas made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2371 holding.
  • UBS AM first reported a position in Arvinas in Q4 2019 and has held it in 27 quarters since.
  • UBS AM's Arvinas position peaked at $15.4M in Q2 2020.
  • 201 funds tracked by Wall St. Rank held Arvinas as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.